• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

May 13, 2021 | Press Releases

MARLBOROUGH, Mass., May 13, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

May 11, 2021 | Press Releases

Data provide proof-of-concept for the application of INTASYL compounds as a way to unlock the potential of CAR-T cell therapy in solid tumorsData presented at the 24th Annual Meeting of the American Society of Gene & Cell TherapyMARLBOROUGH, Mass., May 11, 2021...

Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings

Apr 29, 2021 | Press Releases

MARLBOROUGH, Mass., April 29, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

Apr 10, 2021 | Press Releases

Data presented at the AACR Annual Meeting 2021MARLBOROUGH, Mass., April 10, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi...

Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update

Mar 25, 2021 | Press Releases

MARLBOROUGH, Mass., March 25, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Mar 11, 2021 | Press Releases

MARLBOROUGH, Mass., March 11, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
« Older Entries
Next Entries »

Recent Posts

  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
  • Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
  • Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2026 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us